| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0007 |
| mRNA | SB-525334 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | BRD-K45681478 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | ZM-447439 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | 0.089 | 0.003 |
| mRNA | NVP-BEZ235 | GDSC1000 | pan-cancer | AAC | -0.1 | 0.003 |
| mRNA | JNJ-26854165 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | -0.1 | 0.003 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |